Compare FCN & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCN | CRNX |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | 1996 | 2018 |
| Metric | FCN | CRNX |
|---|---|---|
| Price | $154.95 | $83.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $165.00 | $76.75 |
| AVG Volume (30 Days) | 520.2K | ★ 4.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.51 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $3,788,857,000.00 | $1,039,000.00 |
| Revenue This Year | $7.39 | $720.10 |
| Revenue Next Year | $7.10 | $184.67 |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | ★ 2.44 | N/A |
| 52 Week Low | $137.65 | $25.83 |
| 52 Week High | $189.30 | $83.70 |
| Indicator | FCN | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 93.08 |
| Support Level | $150.66 | $35.03 |
| Resistance Level | $166.46 | N/A |
| Average True Range (ATR) | 5.52 | 1.49 |
| MACD | 1.45 | 5.65 |
| Stochastic Oscillator | 74.65 | 99.79 |
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.